Trial Profile
A double blind, randomized, placebo controlled, crossover study of the effectiveness of oral fampridine in improving upper limb function in progressive multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2021
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 10 Jun 2021 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT02208050 )
- 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology
- 22 Nov 2020 Status changed from recruiting to completed.